Long survivor∗ baseline characteristics and response
| Baseline characteristics . | Guadecitabine (n = 34) . | TC (n = 17) . | Total (N = 51) . |
|---|---|---|---|
| Median age, y (range) | 76.5 (62-93) | 75 (66-82) | 76 (62-93) |
| Sex, n (%) | |||
| Men | 16 (47) | 11 (65) | 27 (53) |
| Women | 18 (53) | 6 (35) | 24 (47) |
| ECOG PS, n (%) | |||
| 0-1 | 26 (76) | 10 (59) | 36 (71) |
| 2-3 | 8 (24) | 7 (41) | 15 (29) |
| Secondary AML, n (%)∗ | 11 (32) | 7 (41) | 18 (35) |
| Poor cytogenetic risk, n (%) | 3 (9) | 4 (23) | 7 (14) |
| Median BM blasts, % (range) | 33 (4-97) | 30 (20-87) | 32 (4-97) |
| WBC <20 000/μL, n (%) | 32 (94) | 16 (94) | 48 (94) |
| Mutation, n (%) | |||
| FLT3- ITD n (%) | 0 | 0 | 0 |
| NPM1 | 5 (15) | 4 (23) | 9 (18) |
| CEBPA | 0 | 0 | 0 |
| TP53 | 0 | 0 | 0 |
| Clinical response n (%) | |||
| CR | 23 (68) | 12 (71) | 35 (69) |
| CRp and/or CRi | 2 (6) | 1 (6) | 3 (6) |
| No response | 9 (26) | 4 (24) | 13 (25) |
| Baseline characteristics . | Guadecitabine (n = 34) . | TC (n = 17) . | Total (N = 51) . |
|---|---|---|---|
| Median age, y (range) | 76.5 (62-93) | 75 (66-82) | 76 (62-93) |
| Sex, n (%) | |||
| Men | 16 (47) | 11 (65) | 27 (53) |
| Women | 18 (53) | 6 (35) | 24 (47) |
| ECOG PS, n (%) | |||
| 0-1 | 26 (76) | 10 (59) | 36 (71) |
| 2-3 | 8 (24) | 7 (41) | 15 (29) |
| Secondary AML, n (%)∗ | 11 (32) | 7 (41) | 18 (35) |
| Poor cytogenetic risk, n (%) | 3 (9) | 4 (23) | 7 (14) |
| Median BM blasts, % (range) | 33 (4-97) | 30 (20-87) | 32 (4-97) |
| WBC <20 000/μL, n (%) | 32 (94) | 16 (94) | 48 (94) |
| Mutation, n (%) | |||
| FLT3- ITD n (%) | 0 | 0 | 0 |
| NPM1 | 5 (15) | 4 (23) | 9 (18) |
| CEBPA | 0 | 0 | 0 |
| TP53 | 0 | 0 | 0 |
| Clinical response n (%) | |||
| CR | 23 (68) | 12 (71) | 35 (69) |
| CRp and/or CRi | 2 (6) | 1 (6) | 3 (6) |
| No response | 9 (26) | 4 (24) | 13 (25) |
Patients who were still alive and on treatment at data cutoff.